共 69 条
[1]
Smolen JS(2017)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update Ann Rheum Dis 76 960-77
[2]
Landewé R(2019)Clinical management for other iatrogenic immunodeficiency-associated lymphoproliferative disorders J Clin Exp Hematop 59 72-92
[3]
Bijlsma J(2007)Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection Am J Hematol 82 1106-9
[4]
Burmester G(2016)Other iatrogenic immunodeficiency-associated lymphoproliferative disorder presenting as primary bone lymphoma in a patient with rheumatoid arthritis Intern Med 55 2259-64
[5]
Chatzidionysiou K(2013)Methotrexate/iatorogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression Eur J Haematol 91 20-8
[6]
Dougados M(2019)Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report BMC Gastroenterol 19 62-51
[7]
Tokuhira M(2004)Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum 50 1740-15
[8]
Tamaru JI(2002)Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France Blood 99 3909-31
[9]
Kizaki M(2007)Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication J Rheumatol 34 322-40
[10]
Miyazaki T(2009)Immunomodulator agent-related lymphoproliferative disorders Mod Pathol 22 1532-8